The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”…
The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”…
The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”…
The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was…
